Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: TG1050

Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015

20150423 – US – EASL2015 TG1050

Published 23 April 2015
Categorized as 2015, Press release, TG1050

Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?

Hung-Chih Yang, et al. Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article Publication

Published 5 February 2015
Categorized as -others, 2015, Publication, TG1050

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication

Published 26 November 2014
Categorized as -others, 2014, Publication, TG1050

Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.

Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication

Published 30 May 2014
Categorized as -others, 2014, Publication, TG1050

TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – Download the article Publication

Published 15 October 2013
Categorized as -others, 2013, Publication, TG1050

TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – Download the article Publication

Published 15 October 2013
Categorized as TG1050

Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.

Houda Boukhebza, et al. Journal of Hepatology, 2013, (58), Supplement 1, S161 – Download the article Publication

Published 3 September 2013
Categorized as -others, 2013, Publication, TG1050

130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.

Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement 1, S57–S58. – Download the article Publication

Published 3 September 2013
Categorized as -others, 2013, Publication, TG1050

Posts pagination

Newer posts Page 1 … Page 3
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu